Search clinical trials for: Placebo to Ammoxetine

Total 60566 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (Ammoxetine)

Major Depressive Disorder (MDD)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

Major Depressive Disorder (MDD)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject

Depression
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

Depression

China
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Terminated

Safety Assessment of Atomoxetine With MA IV Administration

Methamphetamine Dependence | Methamphetamine Abuse

United States
Eli Lilly and Company

Completed

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, France, Austria, Germany, Belgium, Finland, Italy, Netherlands, Portugal, Sweden, Switzerland, United Kingdom
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Eli Lilly and Company

Completed

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Attention Deficit Hyperactivity Disorder | Oppositional Defiant Disorder

Italy
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, United States, Austria, Germany, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

United States, China, Germany, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
Indiana University School of Medicine
Hoffmann-La Roche; Shekhar, Anantha M.D., Ph.D.

Terminated

Efficacy and Safety Study of Clozapine Augmented by Atomoxetine Versus Clozapine Augmented by Placebo in Patients With Chronic Resistant Schizophrenia

Schizophrenia

United States
AstraZeneca

Not yet recruiting

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma (ARTEMISIA)

Asthma

Canada, Denmark, Germany, Spain, United Kingdom
Bayer

Not yet recruiting

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure

Chronic Kidney Disease | Arterial Hypertension | Non-proliferative Diabetic Retinopathy

Germany
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (ACI)

Knee Cartilage Lesion

Austria
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
Bayer

Recruiting

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (SIRIUS)

Thrombolysis | Symptomatic Proximal Deep Vein Thrombosis

Belgium, France, Italy, Netherlands, Canada, Germany, Czechia
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Asthma

United States, Belgium, Germany, Israel, Argentina, France, Denmark, Slovakia
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Active, not recruiting

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (SANTE)

Stillbirths and Infant Mortality

Mali
Eli Lilly and Company

Completed

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Russian Federation
Texas Tech University
EHP Labs

Completed

Metabolic Effects of a Thermogenic Ready-to-drink Beverage

Metabolism | Metabolic Rate

United States
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Eli Lilly and Company

Completed

Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

Attention Deficit Hyperactivity Disorder

Sweden
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Cardior Pharmaceuticals GmbH

Active, not recruiting

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Myocardial Infarction, Acute | Heart Failure, Left Sided

Netherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
Bayer

Completed

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

Hypertension | Chronic Kidney Disease

Germany, Bulgaria
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Marijuana Abuse | Attention Deficit Disorder With Hyperactivity

United States
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Withdrawn

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

Substance Use Disorder | Attention Deficit Hyperactivity Disorder

United States
Rhode Island Hospital

Completed

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

Insomnia | Attention Deficit Hyperactivity Disorder

United States
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
Novartis Pharmaceuticals

Terminated

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers | Part 2 - Patients With Hypertension

United States
Apnimed

Completed

Crossover Trial of AD036 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Eli Lilly and Company

Completed

Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

Attention Deficit Hyperactivity Disorder | Dyslexia

United States
University of Calgary
Cardiac Arrhythmia Network of Canada

Completed

Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope (POST6)

Vasovagal Syncope

Canada
Craig Hospital

Completed

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

Traumatic Brain INjury

United States
Eli Lilly and Company

Completed

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Korea, Republic of, Taiwan, Japan
Eli Lilly and Company

Completed

Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Alzheimer Disease

United States

Search clinical trials for: Placebo to Ammoxetine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations